Aromatase inhibitors: the journey from the state of the art to clinical open questions

doi:10.3389/fonc.2023.1249160

PMC full text:

Front Oncol. 2023; 13: 1249160.

Published online 2023 Dec 22. doi: 10.3389/fonc.2023.1249160

Copyright/LicenseRequest permission to reuse: Copyright © 2023 Generali, Berardi, Caruso, Cazzaniga, Garrone, Minchella, Paris, Pinto and De Placido
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Table 3

Common adverse events in patients undergoing therapy with aromatase inhibitors in an extended and non-extended setting and their incidence pooled risk ratio.

	10 years vs. 5 years			7–8 years vs. 5 years			10 years vs. 7–8 years
	Study	RR (95% CI)	Pooled RR (95% CI)	Study	RR (95% CI)	Pooled RR (95% CI)	Study	RR (95% CI)	Pooled RR (95% CI)
Bone fracture	AERAS	2.44 (1.13, 5.28)	1.27 (1.05, 1.54)*	DATA	1.33 (0.97, 1.81)	1.36 (1.01, 1.84)*	ABCS 16	1.49 (1.10, 2.00)	1.57 (1.22, 2.02)*
	MA17	1.15 (0.91, 1.47)		GIM4 LEAD	1.81 (0.61, 5.37)		IDEAL	1.79 (1.11, 2.90)
	NSABP B-42	1.30 (0.81, 2.11)
	NSABP B-33	1.39 (0.79, 2.45)
Osteopenia/osteoporosis	AERAS	1.18 (1.01, 1.37)	1.24 (1.10, 1.40)*	GIM4 LEAD	1.73 (1.22, 2.45)	1.73 (1.22, 2.45)*	IDEAL	1.70 (1.28, 2.26)	1.70 (1.28, 2.26)*
	MA17	1.35 (1.11, 1.65)
	NSABP B-42	0.50 (0.12, 1.99)
Bone pain (including arthralgia)	AERAS	1.63 (1.28, 2.07)	1.28 (1.11, 1.49)^a,*	ABCSG 6a	1.34 (1.03, 1.73)	1.34 (1.03, 1.73)*	IDEAL	1.11 (0.88, 1.40)	1.11 (0.88, 1.40)
	MA17	1.23 (1.11, 1.36)
	NSABP B-42	1.15 (1.00, 1.32)
	NSABP B-33	1.99 (0.60, 6.58)
Joint stiffness	AERAS	2.42 (1.68, 3.49)	2.40 (1.68, 3.43)*				IDEAL	0.94 (0.66, 1.35)	0.94 (0.66, 1.35)
Joint stiffness	MA17	1.99 (0.37, 10.86)
Myalgia	MA17	1.23 (1.07, 1.41)	1.24 (1.10, 1.39)*
Myalgia	NSABP B-42	1.26 (1.00, 1.59)
Alopecia	MA17	1.42 (1.09, 1.85)	1.42 (1.09, 1.85)*				IDEAL	0.91 (0.64, 1.30)	0.91 (0.64, 1.30)
Depression	MA17	1.09 (0.87, 1.38)	1.12 (0.89, 1.39)				IDEAL	0.82 (0.56, 1.19)	0.82 (0.56, 1.19)
Depression	NSABP B-42	1.39 (0.62, 3.13)
Hypertension	MA17	1.01 (0.80, 1.28)	1.00 (0.81, 1.24)
Hypertension	NSABP B-42	0.96 (0.57, 1.61)

Open in a separate window

RR, risk ratio; CI, confidence interval.

aDue to the heterogeneity between studies, this pooled value was from the random-effects analysis, while others were from the fixed-effect analysis.

*P < 0.05.